CA2662434C - Topical nsaid compositions with increased solubility - Google Patents

Topical nsaid compositions with increased solubility Download PDF

Info

Publication number
CA2662434C
CA2662434C CA2662434A CA2662434A CA2662434C CA 2662434 C CA2662434 C CA 2662434C CA 2662434 A CA2662434 A CA 2662434A CA 2662434 A CA2662434 A CA 2662434A CA 2662434 C CA2662434 C CA 2662434C
Authority
CA
Canada
Prior art keywords
composition
drug
nsaid
compositions
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2662434A
Other languages
English (en)
French (fr)
Other versions
CA2662434A1 (en
Inventor
Monique Spann-Wade
Kenton N. Fedde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GREEN MONIQUE RENATA
Original Assignee
GREEN MONIQUE RENATA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GREEN MONIQUE RENATA filed Critical GREEN MONIQUE RENATA
Publication of CA2662434A1 publication Critical patent/CA2662434A1/en
Application granted granted Critical
Publication of CA2662434C publication Critical patent/CA2662434C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2662434A 2006-09-06 2007-08-28 Topical nsaid compositions with increased solubility Active CA2662434C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US82464206P 2006-09-06 2006-09-06
US60/824,642 2006-09-06
US89388807P 2007-03-09 2007-03-09
US60/893,888 2007-03-09
US11/842,201 2007-08-21
US11/842,201 US20080317684A1 (en) 2006-09-06 2007-08-21 Topical Compositions
PCT/US2007/018892 WO2008030359A2 (en) 2006-09-06 2007-08-28 Topical compositions

Publications (2)

Publication Number Publication Date
CA2662434A1 CA2662434A1 (en) 2008-03-13
CA2662434C true CA2662434C (en) 2017-03-14

Family

ID=39157753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2662434A Active CA2662434C (en) 2006-09-06 2007-08-28 Topical nsaid compositions with increased solubility

Country Status (9)

Country Link
US (4) US20080317684A1 (enExample)
EP (1) EP2066313A2 (enExample)
JP (1) JP2010502701A (enExample)
AR (1) AR062653A1 (enExample)
AU (1) AU2007293460A1 (enExample)
BR (1) BRPI0716881A2 (enExample)
CA (1) CA2662434C (enExample)
MX (1) MX2009002485A (enExample)
WO (1) WO2008030359A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2493465B1 (en) 2009-10-26 2014-10-22 Sephoris Pharmaceuticals, LLC Treatment of sunburn using analgesics and antihistamines
CN103237535A (zh) * 2010-06-30 2013-08-07 盖尔德玛公司 具有spf 30的保湿组合物
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
JP5989095B2 (ja) 2011-05-03 2016-09-07 アポニア ラボラトリーズ インコーポレイテッド イブプロフェンの経皮組成物およびその使用方法
US20130047347A1 (en) * 2011-08-24 2013-02-28 Charles Robert Smith Depilatory Method and Kit
EP2664919A1 (fr) * 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
WO2014151171A1 (en) * 2013-03-15 2014-09-25 The Procter & Gamble Company Personal care compositions
KR102320051B1 (ko) 2013-10-03 2021-10-29 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
CA3052643A1 (en) 2013-11-22 2015-05-28 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices
US20150174254A1 (en) * 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US10137085B2 (en) * 2014-03-19 2018-11-27 Nano And Advanced Materials Institute Limited Nanoemulsion for transdermal delivery and method of making the same
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US20180369174A1 (en) * 2015-12-16 2018-12-27 Achelios Therapeutics, Inc. Methods and compositions for treating peripheral neuropathy
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2019014299A1 (en) * 2017-07-11 2019-01-17 University Of Miami TOPICAL FORMULATIONS OF ACETAMINOPHENE FOR RELIEF RELIEF
DE102018101861A1 (de) * 2018-01-26 2019-08-01 Bertrand Prévôt Kosmetische oder pharmazeutische Zubereitung zur Hautpflege sowie zur Prophylaxe von Muskelkrämpfen
JP2019178110A (ja) * 2018-03-30 2019-10-17 岡山大鵬薬品株式会社 外用剤
FR3083981B1 (fr) * 2018-07-20 2021-01-15 Semiocare Sas Compositions a usage cosmetique et dermatologique
WO2020069450A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
CN109125255A (zh) * 2018-09-30 2019-01-04 天津梅花生物医药科技有限公司 一种滴耳剂
AU2022271274A1 (en) * 2021-05-05 2023-11-23 Smartech Topical, Inc. Topical naproxen formulations and their use
WO2024189661A1 (en) * 2023-03-13 2024-09-19 Jordan University Of Science And Technology A topical composition comprising a ternary metal oxide nanoparticle preservative
CN116747147B (zh) * 2023-04-27 2025-10-17 南京市苗本堂健康管理有限公司 一种靶向祛痘的壬二酸微纳晶混悬液及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2463264A (en) * 1942-12-23 1949-03-01 Ciba Ltd Derivatives of cyclic amidines and process of making same
GB971700A (en) * 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3981681A (en) * 1974-04-16 1976-09-21 Carson Products Company Depilatory formulation
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4049700A (en) * 1976-06-17 1977-09-20 The Upjohn Company Ibuprofen p-hydroxyphenylurea ester
CH614878A5 (enExample) * 1977-03-11 1979-12-28 Charmilles Sa Ateliers
GB2023000B (en) * 1978-06-17 1982-10-13 Kowa Co Antinflammatory analgesic gelled ointments
US4228163A (en) * 1979-03-30 1980-10-14 Dermik Laboratories Method for treating pseudofolliculitis barbae
FR2528420A1 (fr) * 1982-06-15 1983-12-16 Oreal Nouveaux 3-benzylidene camphres, leur procede de preparation et leur utilisation pour la protection contre les rayons uv
IL67445A (en) * 1982-12-09 1985-11-29 Teva Pharma Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids
JPS59222409A (ja) * 1983-06-01 1984-12-14 Nippon Redarii Kk 消炎鎮痛ゲル軟膏剤
US4525344A (en) * 1983-08-15 1985-06-25 Tutsky Ronald J Skin care and shaving composition
US4525348A (en) * 1983-12-19 1985-06-25 Yoshitomi Pharmaceutical Industries, Ltd. Pranoprofen gelled ointment
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
DE3522550A1 (de) * 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
DE3532562A1 (de) * 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
WO1987002891A1 (en) * 1985-11-07 1987-05-21 Pfizer Inc. Compounds and method for the topical treatment of inflammation and pain
DE3621036A1 (de) * 1986-06-24 1988-01-07 Merckle Gmbh Fluessige ibuprofen-zubereitungen
US4775530A (en) * 1987-01-06 1988-10-04 Perricone Nicholas V Method for treatment and prevention of pseudofolliculitis barbae
US5034221A (en) * 1989-06-22 1991-07-23 Rosen Steven E Topical agent and method for the treatment of Pseudofolliculitis barbae
US5087445A (en) * 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US4990658B1 (en) * 1989-12-18 1994-08-30 Ethyl Corp Process for preparing ibuprofen and its alkyl esters
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5237071A (en) * 1991-01-22 1993-08-17 Fairmount Chemical Company, Inc. Process for preparing 2,2'-methylene-bis(6-(2H-benzotriazol-2-yl)-4-hydrocarbyl phenols)
US5166355A (en) * 1991-02-04 1992-11-24 Fairmount Chemical Co., Inc. Process for preparing substituted 2,2'-methylene-bis-[6-(2H-benzotriazol-2-yl)-4-hydrocarbyl-phenols]
GB9212450D0 (en) * 1992-06-11 1992-07-22 Indena Spa New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them
US5315027A (en) * 1993-05-11 1994-05-24 Ethyl Corporation Catalytic process for preparing the alkyl esters of ibuprofen
US5807569A (en) * 1993-05-27 1998-09-15 Smithkline Beecham P.L.C. Topical composition
FI92454C (fi) * 1993-06-30 1994-11-25 Toivo Tammisalo Yhdistetty metsänhakkuu- ja korjuukone
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
BR9611523A (pt) * 1995-11-13 1999-12-28 Pitmy Int Nv Meios de administração para drogas analgésicas, antiinflamatórias e antipiréticas contendo óxido nitroso e composições farmacêuticas contendo tais meios e drogas.
US6084533A (en) * 1997-02-28 2000-07-04 New Mexico State University Technology Transfer Corporation Directional traffic sensor system
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6048533A (en) * 1997-06-30 2000-04-11 Nguyen; Van Bich Turmeric for treating health ailments
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
IL127143A0 (en) * 1998-11-19 1999-09-22 Dpharm Ltd Phospholipid terivatives of non-steroidal anti inflammatory drugs
US6277362B1 (en) * 1999-10-26 2001-08-21 Isw, Inc. After shave treatment preparation
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
GB0126157D0 (en) * 2001-10-31 2002-01-02 Univ Aberdeen Therapeutic compounds
US6620813B1 (en) * 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
AR036755A1 (es) * 2002-10-07 2004-09-29 Thalas Group Inc Una composicion en forma de gel transparente para la administracion de diclofenac sodico a traves de la piel
BRPI0418885A (pt) * 2004-06-07 2007-11-27 Strides Arcolab Ltd composição farmacêutica contendo uma solução estável e clara de fármaco antiinflamatória em cápsula de gelatina mole e processo para a produção da mesma
US20060067958A1 (en) * 2004-09-24 2006-03-30 Unilab Pharmatech, Ltd. Pharmaceutical topical gel compositions
JP2008531693A (ja) * 2005-03-03 2008-08-14 アイ エス ダブリュ グループ インコーポレイテッド 局所用ゲル組成物
US20070053984A1 (en) * 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions

Also Published As

Publication number Publication date
US20150030549A1 (en) 2015-01-29
US20110217248A1 (en) 2011-09-08
WO2008030359A2 (en) 2008-03-13
US20080317684A1 (en) 2008-12-25
AR062653A1 (es) 2008-11-26
AU2007293460A1 (en) 2008-03-13
EP2066313A2 (en) 2009-06-10
BRPI0716881A2 (pt) 2013-10-15
MX2009002485A (es) 2009-05-25
CA2662434A1 (en) 2008-03-13
WO2008030359A3 (en) 2008-07-31
JP2010502701A (ja) 2010-01-28
US20130243707A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
US20150030549A1 (en) Topical compositions
US7138394B2 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20100158993A1 (en) Topical Gel Compositions
EP1858503B1 (en) Topical gels compositions
MX2011008095A (es) La administracion transdermica del diclofenaco, la carbamazepina y la bencidamina.
JPH04210914A (ja) 水アルコール性ゲルを用いるイブプロフエンの経皮デリバリー方法
BRPI0808887A2 (pt) Formulação farmacêutica tópica
US20120157536A1 (en) Composition for transdermal administration of non-steroidal anti-flammatory drug
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US10028927B2 (en) Topical pharmaceutical formulation
ZA200707357B (en) Detection of very virulent infectious bursal disease virus
WO2006096955A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
CN101541321A (zh) 局部用组合物
Kopečná et al. Transdermal permeation and skin retention of diclofenac and etofenamate/flufenamic acid from over-the-counter pain relief products
JP7730863B2 (ja) 外用組成物
AU2004264332B2 (en) Method and composition for treating burned skin
JP2024507266A (ja) ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
US11376213B2 (en) Topical pharmaceutical formulation
CA2500907A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
TR2024002454A1 (tr) Topical compositions comprising nimesulide and diclofenac sodium and a salicylate
Sevastre et al. Influence of some dissolution enhancing agents on the pharmacokinetic profile of meloxicam delivered from hydrophilic ointments
HK1119058A (en) Topical gels compositions

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106